Published in J Occup Environ Med on September 01, 2008
The economic impact of obesity in the United States. Diabetes Metab Syndr Obes (2010) 2.22
Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obes Rev (2011) 1.95
A multicenter randomized controlled trial of a plant-based nutrition program to reduce body weight and cardiovascular risk in the corporate setting: the GEICO study. Eur J Clin Nutr (2013) 1.24
A multi-worksite analysis of the relationships among body mass index, medical utilization, and worker productivity. J Occup Environ Med (2010) 1.20
Participation and cardiovascular risk reduction in a voluntary worksite nutrition and physical activity program. Prev Med (2010) 0.80
The Economic Burden of Obesity by Glycemic Stage in the United States. Pharmacoeconomics (2015) 0.77
Productivity loss due to overweight and obesity: a systematic review of indirect costs. BMJ Open (2017) 0.75
Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes (2011) 3.25
Patterns and correlates of linkage to appropriate HIV care after HIV diagnosis in the US Medicaid population. Sex Transm Dis (2013) 2.92
Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States. Pain Med (2014) 1.79
Prediction of first events of coronary heart disease and stroke with consideration of adiposity. Circulation (2008) 1.56
Retrospective study of adherence to glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes mellitus in the United States. Adv Ther (2014) 1.22
A multi-worksite analysis of the relationships among body mass index, medical utilization, and worker productivity. J Occup Environ Med (2010) 1.20
A perspective on the epidemiology of acetaminophen exposure and toxicity in the United States. Expert Rev Clin Pharmacol (2014) 1.18
A framework to evaluate the economic impact of pharmacogenomics. Pharmacogenomics (2006) 1.15
The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Qual Life Res (2008) 1.11
Preventive services and health behaviors among people with spinal cord injury. J Spinal Cord Med (2005) 1.09
Exposure to potential CYP450 pharmacokinetic drug-drug interactions among osteoarthritis patients: incremental risk of multiple prescriptions. Pain Pract (2010) 1.02
Cost, morbidity, and control of asthma in Hungary: The Hunair Study. J Asthma (2003) 1.02
A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther (2002) 1.00
Risk of infections in rheumatoid arthritis patients switching from anti-TNF agents to rituximab, abatacept, or another anti-TNF agent, a retrospective administrative claims analysis. Semin Arthritis Rheum (2013) 0.98
Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics (2009) 0.95
The impact of overweight and obesity on the direct medical costs of truck drivers. J Occup Environ Med (2009) 0.94
Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ (2014) 0.89
Direct health care costs of patients with type 2 diabetes within a privately insured employed population, 2000 and 2005. J Occup Environ Med (2009) 0.88
Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV. J Manag Care Pharm (2012) 0.86
Use of prescription opioids with abuse-deterrent technology to address opioid abuse. Curr Med Res Opin (2014) 0.86
Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis. Prim Care Companion CNS Disord (2011) 0.84
Economic impact of potential CYP450 pharmacokinetic drug-drug interactions among chronic low back pain patients taking opioids. Pain Pract (2011) 0.84
Health economics perspective of the components of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) (2010) 0.84
Matching documented training needs with practical capacity: lessons learned from Project Public Health Ready. J Public Health Manag Pract (2005) 0.84
Risk of injury associated with attention-deficit/hyperactivity disorder in adults enrolled in employer-sponsored health plans: a retrospective analysis. Prim Care Companion CNS Disord (2011) 0.83
Readmission among hospitalized patients with nonvalvular atrial fibrillation. Am J Health Syst Pharm (2013) 0.82
Fractures in women treated with raloxifene or alendronate: a retrospective database analysis. BMC Womens Health (2013) 0.82
Economic impact of potential drug-drug interactions in opioid analgesics. J Med Econ (2011) 0.81
Association of RSV lower respiratory tract infection and subsequent healthcare use and costs: a Medicaid claims analysis in early-preterm, late-preterm, and full-term infants. J Med Econ (2011) 0.80
Cost comparison of drug-drug and drug-condition interactions in patients with painful diabetic peripheral neuropathy treated with pregabalin versus duloxetine. Am J Health Syst Pharm (2013) 0.80
Employees' willingness to pay to prevent influenza. Am J Manag Care (2010) 0.80
Sources of prescription opioids among diagnosed opioid abusers. Curr Med Res Opin (2015) 0.79
Attending work while sick: implication of flexible sick leave policies. J Occup Environ Med (2010) 0.79
Association between cardiometabolic risk factors and body mass index based on diagnosis and treatment codes in an electronic medical record database. J Manag Care Pharm (2008) 0.78
Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids. Pain Pract (2011) 0.78
Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data. Appl Health Econ Health Policy (2014) 0.78
Characteristics of High-Cost Patients Diagnosed with Opioid Abuse. J Manag Care Spec Pharm (2015) 0.78
Comparative incidence and health care costs of medically attended adverse effects among U.S. Medicaid HIV patients on atazanavir- or darunavir-based antiretroviral therapy. Value Health (2013) 0.78
Impact of body mass index on the incidence of cardiometabolic risk factors in ambulatory care settings over 5 years or more. Value Health (2009) 0.77
STD program activity in state policy processes, 1995 and 2000. Sex Transm Dis (2003) 0.76
Agreement between Internet-based self- and proxy-reported health care resource utilization and administrative health care claims. Value Health (2012) 0.76
State agency policy and program coordination in response to the co-occurrence of HIV, chemical dependency, and mental illness. Public Health Rep (2003) 0.75
Health-care resource use by asthmatics in Croatia. J Asthma (2002) 0.75
Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care (2009) 0.75
Cardiometabolic risk and health care utilization and cost for Hispanic and non-Hispanic women. Popul Health Manag (2009) 0.75
National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom. Int J Cardiol (2003) 0.75
The economic burden of diagnosed opioid abuse among commercially insured individuals. Postgrad Med (2014) 0.75
Comparison between guideline-preferred and nonpreferred first-line HIV antiretroviral therapy. Am J Manag Care (2014) 0.75
Predicting medication persistence to buprenorphine transdermal system. Pain Pract (2014) 0.75
Potential drug-drug and drug-condition interactions among fibromyalgia patients initiating pregabalin or duloxetine: prevalence and health care expenditure impact. Pain Med (2014) 0.75
US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. Curr Med Res Opin (2014) 0.75
Use of the SF-36v2 Health Survey as a Screen for Risk of Major Depressive Disorder in a US Population-based Sample and Subgroup With Chronic Pain. Med Care (2017) 0.75